Targeted therapy for renal cell cancer: current perspectives.

Astrid A.M. van der Veldt*, John B. Haanen, Alfons J.M. van den Eertwegh, Epie Boven

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

In the past 5 years, the introduction of targeted therapy has dramatically changed the outcome of patients with metastatic renal cell cancer (mRCC). In particular, drugs that inhibit signaling of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) have significantly improved the perspectives of patients with this chemoresistant disease. Here, we review the currently approved targeted drugs for the treatment of mRCC. We describe the anti-VEGF monoclonal antibody bevacizumab, the receptor tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib as well as the mTOR inhibitors temsirolimus and everolimus and discuss their role in the contemporary management of patients with mRCC.

Original languageEnglish
Pages (from-to)394-405
Number of pages12
JournalDiscovery medicine
Volume10
Issue number54
Publication statusPublished - Nov 2010

Cite this